المؤلفون: Lambert, Bernard, Meryet-Figuière, Matthieu, Gauduchon, Pascal, Vigneron, Nicolas, Brotin, Emilie, Poulain, Laurent, Denoyelle, Christophe

المساهمون: Biologie et Thérapies Innovantes des Cancers Localement Agressifs (BioTICLA), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by the « Ligue Contre le Cancer » (Calvados’s and Orne committees), the “Conseil Régional de Basse-Normandie”, the French State, the European Community (FEDER funding), Inserm, the University of Caen Low-Normandy and the Comprehensive Cancer Center F. Baclesse (Caen, France). N.V. is a recipient of a doctoral fellowship from the French Ministry for Higher Education and Research. This work was supported by a grant from l'Ecole de l'Inserm Liliane Bettencourt (N.V.).

المصدر: EISSN: 2375-2467 ; RNA & DISEASE ; https://www.hal.inserm.fr/inserm-01279377Test ; RNA & DISEASE, 2015, 2 (3), ⟨10.14800/rd.717⟩

مصطلحات موضوعية: microRNAs, ovarian cancer, Bcl-2 family, EGFR inhibitors, ABT-737, MAPK, Akt, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology

العلاقة: inserm-01279377; https://www.hal.inserm.fr/inserm-01279377Test; https://www.hal.inserm.fr/inserm-01279377/documentTest; https://www.hal.inserm.fr/inserm-01279377/file/717-4041-3-PB.pdfTest

الإتاحة: https://doi.org/10.14800/rd.717Test
https://www.hal.inserm.fr/inserm-01279377Test
https://www.hal.inserm.fr/inserm-01279377/documentTest
https://www.hal.inserm.fr/inserm-01279377/file/717-4041-3-PB.pdfTest

المؤلفون: Stratigos, Alexander John, Garbe, Claus, Dessinioti, Clio, Lebbe, Célèste, Bataille, Véronique, Bastholt, Lars, Dreno, Brigitte, Concetta Fargnoli, Maria Concetta, Forsea, Ana Maria, Frenard, Cecille, Harwood, Catherine Anne, Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, Roland, Kelleners-Smeets, Nicole W.J., Malvehy, Josep, del Marmol, Véronique, Middleton, Mark R., Moreno-Ramirez, David, Pellecani, Giovanni, Peris, Ketty, Saiag, Phillippe, van den Beuken-van Everdingen, Marieke H.J., Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M.M., Grob, Jean Jacques

المساهمون: National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), North & East Hertfordshire NHS Trust Northwood, UK, Odense University Hospital (OUH), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), University of L'Aquila Italy (UNIVAQ), University of Bucharest (UniBuc), Queen Mary University of London (QMUL), Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel (CAU), Medizinische Universität Wien = Medical University of Vienna, Military Medical Academy Belgrade, Serbia (2MA), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University Maastricht, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Université libre de Bruxelles (ULB), University of Oxford, Hospital Universitario Virgen Macarena Sevilla, Spain (HUVM), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart Roma (Unicatt), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré AP-HP, Coimbra Hospital and Universitary Centre Coimbra, Portugal (CHUC), Università degli studi di Trieste = University of Trieste, Princess Máxima Center for Pediatric Oncology, Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Amgen Bristol-Myers Squibb, BMS Pfizer AstraZeneca GlaxoSmithKline, GSK Merck Novartis Roche Sanofi AbbVie Meso Scale Diagnostics, MSD Merck Sharp and Dohme, MSD DUSA Pharmaceuticals Les Laboratories Pierre Fabre Cilag LEO Pharma Research Foundation, The development of the current set of guideline was supported solely by funds of the EADO which were used to mainly support the consensus meeting.Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, grants and personal fees from BMS, personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche, grants and personal fees from Sanofi, outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche, personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dr?no reports grants and personal fees from BMS, personal fees from MSD, grants and personal fees from Roche, grants and personal fees from Fabre, grants and personal fees from Sanofi, outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, grants and personal fees from Sanofi, personal fees from UCB, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma, personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi, Novartis, Merck, Pfizer, Galderma, Meda, Almirall, PellePharm, Leo Pharma, Ceries. Dr. Hauschild reports honoraria and/or research grants from Almirall, BMS, Roche, Novartis, Pierre Fabre, Sun Pharma, Merck Serono, Sanofi-Aventis, Regeneron, MSD/Merck, Philogen, OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen, personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers? honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie, Amgen, Biontech, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Regeneron, Roche, Wyeth. Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development, other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall, ISDIN, Leo Pharma, Galderma, GSK, Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen, outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen, Roche, AstraZeneca, GSK, Novartis, Immunocore, BMS, Eisai and Merck. Institutional funding from Millennium, Vertex, Pfizer, Regeneron, TC Biopharm, BioLineRx, Replimune, outside the submitted work. Dr. Moreno-Ram?rez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia, during the conduct of the study, grants from Novartis, grants and personal fees from Almirall, grants from Leo Pharma, from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie, Almirall, Biogen Celgene, Lilly, Galderma, Leo Pharma, Novartis, Roche, Sanofi, Sun Pharma, Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen, Bristol-Myers Squibb, MSD, Merck Serono, Novartis, Pfizer, Roche-Genentech, Pierre Fabre, and Sanofi, outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi, Sun Pharma, Novartis, Galderma, Roche, Celgene, Almirall, Leo Pharma, Mylan, Difa Cooper, Cieffe Labs, La Roche Posay, Pierre Fabre. Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, AbbVie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis , grants and personal fees from NeraCare , grants and personal fees from BMS , personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche , grants and personal fees from Sanofi , outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb , personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche , personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS, Roche, Novartis, Pierre Fabre, AstraZeneca, Incyte, MSD/Merck, Bayer. Dr. Dréno reports grants and personal fees from BMS , personal fees from MSD, grants and personal fees from Roche , grants and personal fees from Fabre , grants and personal fees from Sanofi , outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall , grants and personal fees from Leo Pharma , personal fees from Janssen, grants and personal fees from Novartis , personal fees from Lilly, grants and personal fees from Sanofi , personal fees from UCB, grants and personal fees from AbbVie , personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma , personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis, Leo Pharma, Solartium, Pierre Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi , Novartis , Merck , Pfizer , Galderma , Meda , Almirall , PellePharm , Leo Pharma , Ceries . Dr. Hauschild reports honoraria and/or research grants from Almirall , BMS , Roche , Novartis , Pierre Fabre , Sun Pharma , Merck Serono , Sanofi-Aventis , Regeneron , MSD/Merck , Philogen , OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen , personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers’ honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from AbbVie , Amgen , Biontech , BMS , Celgene , Galderma , Janssen , Leo , Lilly , Merck , MSD , Novartis , Pierre Fabre , Pfizer , Regeneron , Roche , Wyeth . Advisory board and honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development , other from Janssen-Cilag, other from AbbVie, other from Galderma, outside the submitted work. Dr. Malvehy reports research grants from Almirall , ISDIN , Leo Pharma , Galderma , GSK , Cantabria, participation in advisory board meetings for Almirall, Sun Pharma, BMS, Roche, Novartis, Pierre Fabre. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from AbbVie, grants from Janssen , outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen , Roche , AstraZeneca , GSK , Novartis , Immunocore , BMS , Eisai and Merck . Institutional funding from Millennium , Vertex , Pfizer , Regeneron , TC Biopharm , BioLineRx , Replimune , outside the submitted work. Dr. Moreno-Ramírez has nothing to disclose. Dr. Pellecani reports grants from university of Modena and Reggio Emilia , during the conduct of the study, grants from Novartis , grants and personal fees from Almirall , grants from Leo Pharma , from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie , Almirall , Biogen Celgene , Lilly , Galderma , Leo Pharma , Novartis , Roche , Sanofi , Sun Pharma , Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen , Bristol-Myers Squibb , MSD , Merck Serono , Novartis , Pfizer , Roche-Genentech , Pierre Fabre , and Sanofi , outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi , Sun Pharma , Novartis , Galderma , Roche , Celgene , Almirall , Leo Pharma , Mylan , Difa Cooper , Cieffe Labs , La Roche Posay , Pierre Fabre . Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for BIOCAD, BioInvent, Bristol-Myers Squibb (BMS), CatalYm, Ellipses, GlaxoSmithKline (GSK), HalioDx, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SELLAS, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen, Roche, GSK, Novartis, BMS, Pierre Fabre, Merck, Sanofi, Merck, Pfizer outside the submitted work., European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-03227886Test ; European Journal of Cancer, 2020, 128, pp.83-102. ⟨10.1016/j.ejca.2020.01.008⟩.

مصطلحات موضوعية: Anti-PD-1 antibody, Cemiplimab, Chemotherapy, Cutaneous squamous cell carcinoma, EGFR inhibitors, Follow-up, Locally advanced, Metastatic, Radiotherapy, Surgical excision, Treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32113942; hal-03227886; https://hal.science/hal-03227886Test; PUBMED: 32113942

الإتاحة: https://doi.org/10.1016/j.ejca.2020.01.008Test
https://hal.science/hal-03227886Test

المؤلفون: Charles Ricordel, Luc Friboulet, Francesco Facchinetti, J-C. Soria

المساهمون: Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: Annals of Oncology
Annals of Oncology, Elsevier, 2018, 29 (suppl_1), pp.i28-i37. ⟨10.1093/annonc/mdx705⟩
Annals of Oncology, 2018, 29 (suppl_1), pp.i28-i37. ⟨10.1093/annonc/mdx705⟩

مصطلحات موضوعية: 0301 basic medicine, Lung Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Drug resistance, Somatic evolution in cancer, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, medicine, Biomarkers, Tumor, Animals, Humans, [CHIM]Chemical Sciences, Osimertinib, Epidermal growth factor receptor, Progression-free survival, Lung cancer, Protein Kinase Inhibitors, EGFR inhibitors, Clinical Trials as Topic, biology, business.industry, Hematology, Oncogene Addiction, medicine.disease, Xenograft Model Antitumor Assays, Progression-Free Survival, 3. Good health, ErbB Receptors, Gene Expression Regulation, Neoplastic, Disease Models, Animal, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Tumor Escape, business, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8fc1909aa8b6b231b48fc0b0da3b19Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01744406Test

المؤلفون: Elizabeth Fabre, Coralie L. Guerin, Ludivine Laurans, Abdelilah Wakkach, Hafid Ait-Oufella, Jérémie Lemarié, Pierre-Louis Tharaux, Jérémie Joffre, Léa Guyonnet, Ziad Mallat, Mikael Maître, Wared Nour-Eldine, Jonas Friard, Simon Bourcier, Lynda Zeboudj, Alain Tedgui

المساهمون: Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Luxembourg Institute of Health (LIH), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de PhysioMédecine Moléculaire (LP2M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Génétique, physiopathologie et ingénierie du tissu osseux (GéPITOS), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Centre de Recherche Cardiovasculaire de Lariboisiere, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Réanimation Médicale [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Mallat, Ziad [0000-0003-0443-7878], Apollo - University of Cambridge Repository, Wakkach, Abdelilah, Université Nice Sophia Antipolis (1965 - 2019) (UNS)

المصدر: Journal of the American College of Cardiology
Journal of the American College of Cardiology, Elsevier, 2018, 71 (2), pp.160-172. ⟨10.1016/j.jacc.2017.10.084⟩
Journal of the American College of Cardiology, 2018, 71 (2), pp.160-172. ⟨10.1016/j.jacc.2017.10.084⟩

مصطلحات موضوعية: 0301 basic medicine, CD4-Positive T-Lymphocytes, [SDV.IMM] Life Sciences [q-bio]/Immunology, Lymphocyte, T cell, Inflammation, Antineoplastic Agents, lymphocyte, T-Lymphocytes, Regulatory, 03 medical and health sciences, Erlotinib Hydrochloride, Mice, 0302 clinical medicine, Immune system, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, In vivo, medicine, Animals, Epidermal growth factor receptor, Protein Kinase Inhibitors, ComputingMilieux_MISCELLANEOUS, EGFR inhibitors, Immunity, Cellular, biology, business.industry, Atherosclerosis, immunity, Plaque, Atherosclerotic, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, ErbB Receptors, 030104 developmental biology, medicine.anatomical_structure, inflammation, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Erlotinib, medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3eb0c76c463dde24368ee41fc0ed91Test
https://hal.archives-ouvertes.fr/hal-02402850Test

المؤلفون: Julien Taieb, C.-B. Levaché, Géraldine Perkins, K. Le Malicot, L. Saban-Roche, Gunnar Folprecht, John Bridgewater, Josep Tabernero, J. Thaler, J.F. Emile, J.-L. Van Laethem, Pierre Laurent-Puig, Enrico Mini, E. Van Cutsem, Côme Lepage, Ralyath Balogoun, Claire Mulot, Aziz Zaanan, S. Fratte, L.N. Petersen

المساهمون: Service d'Hépato-gastro-entérologie et endoscopies digestives [ [Hôpital Européen Georges Pompidou], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Fédération Francophone de la Cancérologie Digestive, FFCD, Département de médecine expérimentale et clinique [Université de Florence], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Service de pathologie [CHU Ambroise Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Université Paris Descartes - Paris 5 (UPD5), CH Belfort-Montbéliard, Polyclinique Francheville, Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Klinikum Wels Grieskirchen, Rigshospitalet [Copenhagen], Copenhagen University Hospital, UCL Cancer Institute [University College London], University College of London [London] (UCL), Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of General Medical Oncology [Leuven], University Hospitals Leuven [Leuven], Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), University of Florence (UNIFI), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique ( MEPPOT - U1147 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), University of Florence, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Ambroise Paré, Université Paris Descartes - Paris 5 ( UPD5 ), Centre Hospitalier Universitaire de Saint-Etienne ( CHU de Saint-Etienne ), University College of London [London] ( UCL ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM )

المصدر: Annals of Oncology
Annals of Oncology, Elsevier, 2017, 28 (4), pp.824-830. ⟨10.1093/annonc/mdw687⟩
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (4), pp.824-830. ⟨10.1093/annonc/mdw687⟩
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (4), pp.824-830. 〈https://academic.oup.com/annonc/article-abstract/28/4/824/2748099?redirectedFrom=fulltextTest〉. 〈10.1093/annonc/mdw687〉

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Neuroblastoma RAS viral oncogene homolog, Organoplatinum Compounds, DNA Mutational Analysis, Leucovorin, Kaplan-Meier Estimate, medicine.disease_cause, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, stage III colon cancer, FOLFOX, Antineoplastic Combined Chemotherapy Protocols, cetuximab, Epidermal growth factor receptor, EGFR inhibitors, education.field_of_study, biology, Cetuximab, Hematology, Middle Aged, 3. Good health, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Colonic Neoplasms, Female, Fluorouracil, KRAS, RAS mutations, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Adenocarcinoma, BRAF mutations, Disease-Free Survival, Young Adult, 03 medical and health sciences, adjuvant, Internal medicine, medicine, Humans, education, neoplasms, Aged, Neoplasm Staging, business.industry, Cancer, medicine.disease, phase III, digestive system diseases, 030104 developmental biology, Mutation, ras Proteins, biology.protein, prognosis, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9601c234f9ac7ac8046b7dc8d8594d9eTest
https://hal.archives-ouvertes.fr/hal-01685765Test

المؤلفون: Séverine Ravez, Omar Castillo-Aguilera, Laurence Goossens, Patrick Depreux

المساهمون: Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Institut de Chimie Pharmaceutique Albert Lespagnol (ICPAL), Université de Lille, Droit et Santé, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

المصدر: Expert Opinion on Therapeutic Patents
Expert Opinion on Therapeutic Patents, 2015, Expert Opinion on Therapeutic Patents, 25, pp.789-804. ⟨10.1517/13543776.2015.1039512⟩

مصطلحات موضوعية: Pharmacology, Quinazoline derivatives, Egfr inhibition, [SDV]Life Sciences [q-bio], Therapeutic protein, Antineoplastic Agents, General Medicine, Kinase inhibition, Cancer treatment, Patents as Topic, chemistry.chemical_compound, chemistry, Biological property, Drug Design, Neoplasms, Drug Discovery, Quinazoline, Quinazolines, Animals, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors, EGFR inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6822e58146562f19573afdabc9ee5054Test
https://hal.univ-lille.fr/hal-03533888Test

المؤلفون: Bernard Lambert, Matthieu Meryet-Figuière, Laurent Poulain, Emilie Brotin, Christophe Denoyelle, Nicolas Vigneron, Pascal Gauduchon

المساهمون: Biologie et Thérapies Innovantes des Cancers Localement Agressifs (BioTICLA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), This work was supported by the « Ligue Contre le Cancer » (Calvados’s and Orne committees), the 'Conseil Régional de Basse-Normandie', the French State, the European Community (FEDER funding), Inserm, the University of Caen Low-Normandy and the Comprehensive Cancer Center F. Baclesse (Caen, France). N.V. is a recipient of a doctoral fellowship from the French Ministry for Higher Education and Research. This work was supported by a grant from l'Ecole de l'Inserm Liliane Bettencourt (N.V.)., DENOYELLE, Christophe

المصدر: RNA & DISEASE
RNA & DISEASE, Smart Science & Technology LLC, USA, 2015, 2 (3), ⟨10.14800/rd.717⟩

مصطلحات موضوعية: Combination therapy, [SDV]Life Sciences [q-bio], Context (language use), [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Bioinformatics, [SDV.CAN] Life Sciences [q-bio]/Cancer, Bcl-2 family, Ovarian carcinoma, microRNA, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, medicine, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, EGFR inhibitors, ABT-737, Akt, General Medicine, medicine.disease, MAPK, 3. Good health, microRNAs, [SDV] Life Sciences [q-bio], [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, ovarian cancer, Ovarian cancer

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2322f7cb942e2d4359cbc1cb5d6421dTest
https://www.hal.inserm.fr/inserm-01279377/documentTest

المؤلفون: Nagako Kawashima, Yongmin Zhang, Matthieu Sollogoub, S Hakomori, Kazuko Handa, Huanhuan Qu, Webster K. Cavenee, Marlin Lobaton, Zhenyuan Zhu

المساهمون: Institut Parisien de Chimie Moléculaire (IPCM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Shanghai Institute of Materia Medica, Glycochimie Organique Biologique et Supramoléculaire (GOBS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Ludwig Institute for Cancer Research, University of California [San Diego] (UC San Diego), University of California (UC)-University of California (UC), University of Washington [Seattle], Institut de Chimie du CNRS (INC)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie du CNRS (INC)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), University of California-University of California

المصدر: Oncology Letters
Oncology Letters, 2014, 7 (4), pp.933--940. ⟨10.3892/ol.2014.1887⟩
Oncology Letters, Spandidos Publications, 2014, 7 (4), pp.933--940. ⟨10.3892/ol.2014.1887⟩

مصطلحات موضوعية: GM3, Cancer Research, Motility, EGFR activation, [CHIM]Chemical Sciences, Epidermal growth factor receptor, ComputingMilieux_MISCELLANEOUS, EGFR inhibitors, chloro-derivatives of GM3, glycosphingolipids, biology, Cell growth, Autophosphorylation, Articles, Cell cycle, 3. Good health, Cell biology, carbohydrates (lipids), cell proliferation, Oncology, Epidermoid carcinoma, Immunology, biology.protein, lipids (amino acids, peptides, and proteins), A431 cells

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b47a05db8020f350e39ec997e8987b1Test
https://hal.science/hal-01708000Test

المؤلفون: Emilie Sbidian, Hélène Blons, Hélène Roussel, Daniel Brasnu, Patrick Bruneval, Florient Scotté, Cécile Badoual, Jérôme Cros, Pierre Laurent-Puig, Eric Tartour, Stéphane Hans

المساهمون: Laboratoire d'Investigation Clinique (LIC), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'oto-rhino-laryngologie et chirurgie cervico-faciale [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 (LPP), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Cytokines et Immunologie des Tumeurs Humaines (U753), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomo-pathologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Investigation Clinique ( LIC ), Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 ( LPP ), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique ( CNRS ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Cytokines et Immunologie des Tumeurs Humaines ( U753 ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)

المصدر: Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2013, 24, pp.2624-2629
Annals of Oncology, Elsevier, 2013, 24, pp.2624-2629
Annals of Oncology, 2013, 24 (10), pp.2624-2629. ⟨10.1093/annonc/mdt338⟩

مصطلحات موضوعية: Neuroblastoma RAS viral oncogene homolog, Male, Survival, Receptor, ErbB-2, medicine.medical_treatment, medicine.disease_cause, Myoepithelioma, Targeted therapy, 0302 clinical medicine, Molecular Targeted Therapy, [SHS.LANGUE]Humanities and Social Sciences/Linguistics, ComputingMilieux_MISCELLANEOUS, EGFR inhibitors, 0303 health sciences, Hematology, Middle Aged, Salivary Gland Neoplasms, targeted therapies, 3. Good health, ErbB Receptors, Proto-Oncogene Proteins c-kit, Oncology, Chemotherapy, Adjuvant, Receptors, Androgen, 030220 oncology & carcinogenesis, [ SHS.LANGUE ] Humanities and Social Sciences/Linguistics, Female, KRAS, Genotype, EGFR, Disease-Free Survival, 03 medical and health sciences, Mucoepidermoid carcinoma, HER2, medicine, Androgen Receptor Antagonists, Biomarkers, Tumor, Humans, HRAS, 030304 developmental biology, business.industry, Myoepithelial cell, Cancer, Oncogenes, medicine.disease, High-Throughput Screening Assays, C-KIT, Cancer research, Carcinoma, Mucoepidermoid, malignant salivary gland tumours, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66eba27c0c68abf34669c9ed695c4e27Test
https://halshs.archives-ouvertes.fr/halshs-01457188Test

المؤلفون: Garcia, Raquel, Kubicek, Vojtech, Drahos, Bohuslav, Gano, Lurdes, Santos, Isabel C., Antonio, Paulo, Tóth, Éva, Santos, Isabel Paula

المساهمون: Centre de biophysique moléculaire (CBM), Université d'Orléans (UO)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS)

المصدر: Mettalomics ; https://hal.science/hal-00529335Test ; Mettalomics, 2010, 2 (8), pp.571-580. ⟨10.1039/c004797j⟩

مصطلحات موضوعية: GROWTH-FACTOR RECEPTOR, STRUCTURAL-CHARACTERIZATION, TYROSINE KINASE, EGFR INHIBITORS, CANCER, BIOMARKER, AGENTS, TUMORS, DERIVATIVES, TC-99M

العلاقة: hal-00529335; https://hal.science/hal-00529335Test

الإتاحة: https://doi.org/10.1039/c004797jTest
https://hal.science/hal-00529335Test